How do I set a price alert for CLLS?

To set a CLLS price alert on Stock Alarm Pro, navigate to the CLLS quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for CLLS?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for CLLS. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for CLLS?

Stock Alarm Pro supports over 125 trigger types for CLLS: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about CLLS price changes?

CLLS alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for CLLS alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for CLLS and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

CLLS Company Intelligence - Business Model, Drivers & Risks

Demo Sign up Log In

Cellectis S.A.(CLLS)

NASDAQUpdated 11:40 AM ESTAbout this dataData status

$1.08▼-0.09 (-7.69%)Earnings · Nov 13

WatchlistChart Studio

Explore More

CLLS Financial Metrics

Explore 130+ historical metrics & ratios

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.

Cellectis is a French clinical-stage biotechnology company developing allogeneic CAR-T cell therapies using proprietary TALEN gene-editing technology. The company's lead programs target hematological malignancies (UCART19, UCART22) and solid tumors (UCART123), with manufacturing facilities in Paris and Raleigh, NC. As a pre-revenue biotech, the stock trades on clinical trial milestones, regulatory progress, and cash runway visibility.

HealthcareGene Editing & Cell Therapy Biotechnologylow - Clinical-stage biotech with high fixed R&D costs (clinical trials, manufacturing facilities, regulatory compliance) and minimal variable costs. Operating leverage only materializes post-commercialization when manufacturing scales. Current burn rate estimated $60-80M annually with limited ability to flex costs short-term given multi-year trial commitments and facility obligations.

Business Overview

01Collaboration and licensing agreements (historically ~85-90% when present, primarily Servier partnership)

02Research grants and tax credits from French government (CIR tax credit program)

03Potential future product sales from commercialized CAR-T therapies (not yet generating revenue)

Cellectis operates a platform business model built on TALEN gene-editing IP, licensing technology to partners while advancing proprietary allogeneic (off-the-shelf) CAR-T programs. Unlike autologous CAR-T (Kymriah, Yescarta), allogeneic therapies use donor cells, enabling scalable manufacturing and lower cost-per-dose economics. Revenue historically derived from upfront payments, milestone achievements, and royalties from partners like Servier. The company's competitive advantage lies in TALEN precision (vs CRISPR), established GMP manufacturing infrastructure, and first-mover positioning in allogeneic CAR-T. Pricing power depends on demonstrating clinical superiority and manufacturing cost advantages over autologous competitors.

What Moves the Stock

Clinical trial data readouts (ORR, CR rates, durability of response for UCART19/22/123 programs)

FDA/EMA regulatory interactions (IND clearances, clinical hold resolutions, BLA submission timelines)

Partnership announcements and milestone payments (licensing deals, collaboration expansions)

Cash position updates and financing events (equity raises, debt facilities, runway extension)

Competitive landscape shifts (rival allogeneic CAR-T data from Allogene, Precision BioSciences, CRISPR Therapeutics)

Watch on Earnings

Cash and cash equivalents balance (runway visibility, typically 18-24 months targeted)Clinical trial enrollment rates and patient dosing milestonesR&D expense burn rate and operating expense guidancePartnership revenue recognition and milestone achievement timingManufacturing capacity utilization and cost-per-dose metrics

Risk Factors

Clinical trial failure risk - allogeneic CAR-T faces unique challenges including host-versus-graft rejection, limited persistence, and unproven efficacy vs autologous therapies across multiple indications

Regulatory pathway uncertainty - FDA/EMA requirements for allogeneic cell therapies continue evolving, with potential for clinical holds, additional safety studies, or manufacturing process changes

Competitive technology displacement - CRISPR-based editing platforms may offer advantages over TALEN, while in vivo gene editing could bypass ex vivo cell therapy manufacturing entirely

Reimbursement uncertainty - payer willingness to cover allogeneic CAR-T at premium pricing vs established autologous therapies remains unproven

Allogene Therapeutics (NASDAQ: ALLO) advancing competing allogeneic CAR-T pipeline with TurboCAR technology and stronger cash position (~$400M+ vs Cellectis)

Autologous CAR-T incumbents (Gilead/Kite, BMS/Juno, Novartis) improving manufacturing turnaround times and reducing costs, narrowing allogeneic advantage

CRISPR Therapeutics and Precision BioSciences developing alternative gene-editing approaches for allogeneic cell therapies with potentially superior profiles

Cash runway risk - with ~$60-80M annual burn and $0.4B market cap, company likely requires additional financing within 12-18 months, risking significant dilution at current valuation

Debt/Equity ratio of 0.92 indicates material debt obligations that consume cash and limit financial flexibility during clinical development phase

Current ratio of 1.49 suggests adequate near-term liquidity but limited buffer for unexpected trial delays or regulatory setbacks requiring additional capital

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - Pre-revenue biotech with minimal direct GDP linkage. Clinical trial timelines and regulatory processes largely insulated from economic cycles. However, severe recessions can impact: (1) ability to raise capital at favorable terms, (2) partner pharmaceutical companies' willingness to fund collaborations, and (3) hospital system capacity to enroll patients in trials during healthcare system stress.

Interest Rates

Rising rates create significant headwinds through multiple channels: (1) Higher discount rates compress NPV of distant future cash flows (typical for early-stage biotech), (2) Increased cost of capital makes equity financing more dilutive, (3) Risk-off sentiment shifts capital away from speculative growth stocks toward safer assets, (4) Competing yields from bonds reduce relative attractiveness of non-income-generating equities. The 10-year Treasury yield serves as the primary valuation benchmark for long-duration biotech assets.

Credit

Moderate - While not operationally credit-dependent, access to capital markets is critical for survival. Widening credit spreads and risk-off environments can severely constrain ability to raise equity or debt financing, potentially forcing unfavorable dilution or partnership terms. High-yield credit conditions serve as proxy for risk appetite in speculative biotech financing.

Live Conditions

S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth - Attracts high-risk-tolerance investors seeking asymmetric returns from clinical-stage biotech with platform technology potential. Typical holders include specialized healthcare hedge funds, biotech-focused venture investors, and retail momentum traders. Not suitable for value or income investors given pre-revenue status, negative cash flows, and binary clinical/regulatory outcomes. The 185% one-year return reflects speculative momentum trading around clinical catalysts.

high - Clinical-stage biotech with $400M market cap exhibits extreme volatility around binary events (trial data, regulatory decisions, financing announcements). The -25% three-month return followed by +185% one-year return demonstrates characteristic boom-bust cycles. Implied volatility typically 80-120% around major catalysts. Low float and limited institutional ownership amplify price swings on modest volume.

Key Metrics to Watch

Quarterly cash burn rate and ending cash balance (runway calculation)

Clinical trial enrollment velocity and patient dosing milestones across UCART programs

Objective response rates (ORR) and complete response (CR) rates in Phase I/II trials

Manufacturing cost-per-dose trends and facility utilization rates

Competitor clinical trial results (Allogene, CRISPR Therapeutics allogeneic programs)

NASDAQ Biotechnology Index (NBI) performance as sector sentiment indicator

Biotech IPO and follow-on offering activity as capital markets health proxy

Explore More

S&P 500 Sector Leaderboards

Fundamental Metric Rankings

Business Overview

Risk Factors

Macro Sensitivity

Profile